Participants in the study will be monitored over a period of up to one year. During this time, researchers will observe whether the medication helps reduce the risk of complications or the need for surgery to remove the gallbladder, known as a cholecystectomy. Some participants will receive the medication, while others will receive a placebo, which is a capsule that looks like the medication but does not contain the active ingredient.

The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The trial aims to provide valuable information on whether Ursodeoxycholic Acid can effectively prevent complications after an initial episode of acute biliary pancreatitis.

Participants in the study will be randomly assigned to receive either Simvastatin or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be “triple-blind,” meaning that the participants, the healthcare providers, and the researchers do not know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The treatment period will last for up to 12 months, during which participants will take the medication orally in the form of a film-coated tablet.

The main goal of the study is to compare the number of new pancreatitis episodes between those taking Simvastatin and those taking the placebo. Additionally, the study will look at other factors such as the development of new health issues like diabetes or pancreatic insufficiency, the severity of pancreatitis episodes, and the number of hospital visits due to abdominal pain. The results of this study could provide valuable information on whether Simvastatin can be an effective treatment for preventing recurrent pancreatitis.

The purpose of the study is to determine which of these fluid therapies results in better outcomes for patients with acute pancreatitis. Patients will receive one of these solutions as part of their treatment to see if it can help improve their condition or prevent it from becoming more severe. This study takes place in multiple hospitals, allowing researchers to gather data from various locations.

By understanding which fluid therapy works best, this study aims to influence treatment methods for patients with acute pancreatitis, improving care for those experiencing this condition. If a particular fluid solution shows better results, it could change routine practices used in treating this common disease.

Participants in the study will receive either the omega-3 fatty acid infusion or standard medical care. The study will monitor the effects of the treatment over a period of time to determine if it helps in reducing complications associated with severe acute pancreatitis. The trial will also look at other factors such as the length of hospital stay, the need for additional medical interventions, and any side effects that may occur.

The study aims to provide valuable information on whether omega-3 fatty acids can be a beneficial addition to the treatment of severe acute pancreatitis, potentially improving outcomes for patients by reducing inflammation and supporting organ function. The results will be evaluated after a 180-day study period to assess the effectiveness of the treatment in preventing new organ failure and reducing mortality rates.

The purpose of the study is to investigate how these two solutions affect the severity and safety of acute pancreatitis. The trial will look at how often patients experience moderately severe to severe forms of the condition. It will also monitor for any safety concerns, such as fluid overload, which is when the body has too much fluid, or issues like kidney injury, high levels of potassium or calcium in the blood, and acidosis, which is when there is too much acid in the body.

Participants in the study will receive one of the two solutions and will be monitored for 30 days to see how their condition progresses. The study will also track any complications, the need for additional treatments, and the overall recovery process, including how quickly patients can start eating normally again. The trial aims to provide valuable information on which solution might be more effective and safer for treating acute pancreatitis.